Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current...
Enregistré dans:
Auteurs principaux: | Pecenak J, Novotny V |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2c174cbcfa864d1aa3e1fa12daf2caec |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Agomelatine as monotherapy for major depression: an outpatient, open-label study
par: Pecenak J, et autres
Publié: (2013) -
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
par: Fornaro M, et autres
Publié: (2013) -
Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
par: Robert H Howland
Publié: (2009) -
Quetiapine monotherapy for bipolar depression
par: Michael E Thase
Publié: (2008) -
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
par: Berman R, et autres
Publié: (2011)